Borviz 2.5mg Injection contains Bortezomib, is an anticancer drug used to treat certain hematologic malignancies. Borviz is a proteasome inhibitor that affects the proteasome's activity, causing regulatory proteins to accumulate in the cell.

Brand name: Borviz

Composition: Bortezomib

Mechanism of action:

Bortezomib is a proteasome inhibitor. It acts by blocking the proteasome, a cellular component that degrades ubiquitinated proteins. This causes the buildup of pro-apoptotic proteins and cell cycle regulators, which eventually induces apoptosis (programmed cell death) in malignant cells, particularly those with hematological malignancies. Consult a healthcare practitioner for particular treatment regimens.

Uses: 

·       Multiple Myeloma

·       Lymphoma

Side effects: 

·         Fatigue

·         Nausea

·         Vomiting

·         Diarrhea

·         Numbness

·         Tingling

·         Pain

·         Thrombocytopenia

·         Neutropenia

·         Anemia

·         Heart failure

·         Deep vein thrombosis

Dosage and Administration:

Administered by intravenous or subcutaneous injection.

Safety Advise:

Kidney  

Patients with severe renal disease should exercise caution while using Borviz 2.5mg Injection. Kindly speak with your healthcare provider.

Liver  

Borviz 2.5mg Injection should be administered with caution to individuals suffering from liver disease. Kindly speak with your healthcare provider.

Pregnancy  

Borviz 2.5mg Injection is not recommended for usage during pregnancy since there is clear evidence of danger to the developing infant. Kindly speak with your healthcare provider.

Breast Feeding  

Borviz 2.5mg Injection is not safe to use when breast feeding. Kindly speak with your healthcare provider.

Alcohol  

Borviz 2.5mg Injection of alcohol may produce extreme sleepiness. Kindly speak with your healthcare provider.

Storage:

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.

How to use this Medication?

Your dose plan will be determined by your disease, additional drugs you are taking, and how your body responds to therapy.

Make sure to notify your doctor how you're feeling during your therapy

If you develop adverse effects from Bortezomib, your doctor may temporarily discontinue your therapy or reduce your dose. 

References:

1.      Paramore A, Frantz S. Bortezomib. Nature reviews Drug discovery. 2003 Aug 1;2(8):611-2.

2.      Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent patents on anti-cancer drug discovery. 2006 Nov 1;1(3):397-403.

3.      Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database of Systematic Reviews. 2016(4).

4.      Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R. Bortezomib: understanding the mechanism of action. Mol Cancer Ther. 2011 Nov 1;10(11):2029-30.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Intas Pharmaceuticals Ltd

Address: Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India.

Country of origin: India